Cochrane · systematic review · CD011438
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta₂‐agonists (LABA) for adults with asthma
Kew, KM, Evans, DJW, Anderson, DE, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 2 · 28.6%Moderate 2 · 28.6%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Long‐acting muscarinic antagonists (LAMA) add‐on compared with long‐acting beta2‐agonists (LABA) add‐on for adults with asthma
Population: adults with asthma not well controlled on ICS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbations (OCS) Long‐acting muscarinic antagonists (LAMA) add‐on vs long‐acting beta2‐agonists (LABA) add‐on | OR 1.05 [0.5, 2.18] | 3 studies · 1755 participants | Low Downgraded: imprecision |
AQLQ total 1 = severely impaired; 7 = not impaired at all 22 weeks Long‐acting muscarinic antagonists (LAMA) add‐on vs long‐acting beta2‐agonists (LABA) add‐on | no estimate extracted | 4 studies · 1745 participants | High |
Serious adverse events 22 weeks Long‐acting muscarinic antagonists (LAMA) add‐on vs long‐acting beta2‐agonists (LABA) add‐on | OR 0.84 [0.41, 1.73] | 4 studies · 2012 participants | Low Downgraded: imprecision, inconsistency |
Exacerbations (hospital) Long‐acting muscarinic antagonists (LAMA) add‐on vs long‐acting beta2‐agonists (LABA) add‐on | OR 0.72 [0.18, 2.92] | 4 studies · 2022 participants | Very low Downgraded: imprecision, inconsistency |
Trough FEV1 (L) Long‐acting muscarinic antagonists (LAMA) add‐on vs long‐acting beta2‐agonists (LABA) add‐on | no estimate extracted | 4 studies · 1745 participants | Moderate Downgraded: imprecision, inconsistency |
ACQ total 0 = no impairment; 6 = maximum impairment 23 weeks Long‐acting muscarinic antagonists (LAMA) add‐on vs long‐acting beta2‐agonists (LABA) add‐on | no estimate extracted | 3 studies · 1483 participants | High |
Adverse events (all) Long‐acting muscarinic antagonists (LAMA) add‐on vs long‐acting beta2‐agonists (LABA) add‐on | OR 1.11 [0.92, 1.35] | 3 studies · 1839 participants | Moderate Downgraded: imprecision |